CRDL | Cardiol Therapeutics Inc. | [NASD]
Index- P/E- EPS (ttm)-0.46 Insider Own4.42% Shs Outstand64.09M Perf Week14.20%
Market Cap57.89M Forward P/E- EPS next Y-0.35 Insider Trans0.00% Shs Float61.11M Perf Month14.22%
Income-29.10M PEG- EPS next Q-0.12 Inst Own13.99% Short Float / Ratio0.24% / 1.44 Perf Quarter17.20%
Sales- P/S- EPS this Y32.40% Inst Trans- Short Interest0.15M Perf Half Y25.99%
Book/sh0.71 P/B0.95 EPS next Y23.50% ROA-45.20% Target Price- Perf Year-40.89%
Cash/sh0.58 P/C1.17 EPS next 5Y- ROE-53.00% 52W Range0.45 - 1.70 Perf YTD32.14%
Dividend- P/FCF- EPS past 5Y-46.60% ROI- 52W High-60.36% Beta0.87
Dividend %- Quick Ratio7.30 Sales past 5Y- Gross Margin- 52W Low49.76% ATR0.05
Employees17 Current Ratio7.30 Sales Q/Q- Oper. Margin- RSI (14)58.41 Volatility8.20% 8.37%
OptionableYes Debt/Eq0.00 EPS Q/Q23.50% Profit Margin- Rel Volume0.58 Prev Close0.68
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume103.86K Price0.67
Recom1.50 SMA209.25% SMA5019.48% SMA200-3.86% Volume60,580 Change-0.88%
May-09-23 07:15AM
Mar-29-23 07:27AM
Mar-07-23 07:27AM
Jan-17-23 02:59PM
07:27AM Loading…
Dec-12-22 07:27AM
Nov-14-22 05:00PM
Nov-07-22 07:27AM
Oct-25-22 06:30AM
Oct-03-22 07:27AM
Sep-28-22 08:20AM
Sep-27-22 09:05AM
Aug-03-22 07:29AM
Jul-12-22 06:14AM
Jun-29-22 10:07AM
10:07AM Loading…
Jun-27-22 10:07AM
Jun-09-22 04:05PM
May-27-22 01:00PM
May-24-22 07:00AM
May-19-22 07:27AM
May-17-22 07:27AM
May-02-22 02:42PM
Mar-24-22 07:27AM
Mar-22-22 07:27AM
Mar-15-22 07:27AM
Mar-01-22 07:27AM
Feb-02-22 06:30AM
Jan-19-22 07:27AM
Nov-05-21 09:18AM
Nov-04-21 08:52AM
08:36AM Loading…
Nov-03-21 08:36AM
Nov-02-21 04:04PM
Oct-25-21 07:27AM
Oct-18-21 07:27AM
Sep-16-21 07:27AM
Sep-10-21 04:33PM
Sep-07-21 07:27AM
Aug-24-21 07:27AM
Aug-19-21 06:52AM
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.